|
Dr. Muneesh Tewari
After graduating with a bachelor’s degree in biochemistry from Case Western Reserve University, Tewari came to the University of Michigan where he earned both a PhD in Cell and Molecular Biology and a medical degree. Dr. Tewari then moved to Boston, where he completed a fellowship in Medical Oncology at Dana-Farber Cancer Institute. Following a postdoctoral research fellowship in systems biology and genetics at Dana-Farber Cancer Institute/Harvard Medical School, Tewari joined the faculty of the Fred Hutchinson Cancer Research Center in Seattle in 2005. In 2014, he relocated his lab to his alma mater, the University of Michigan.
|
|
|
|
|
|
Dr. Muneesh Tewari is an attending oncologist and a leading researcher in the exciting field of extracellular nucleic acids. Over the years, Tewari has developed innovative tools to measure exRNAs and cell-free DNA in body fluids for the diagnosis and monitoring of disease.
When Dr. Tewari began his MD/PhD at the University of Michigan in 1990, the world was largely unfamiliar with micro RNA (miRNA). When Dr. Tewari received his degree seven years later, a single miRNA had been discovered. The conversation about miRNA was just beginning as he headed to Harvard for his postdoctoral research.
Tewari first heard about these nucleotide sequences while working alongside a colleague researching protein networks. Captivated by the ability of miRNAs to prevent genes from being translated into proteins, Tewari dedicated much of his time to investigating their full capabilities, particularly those of circulating miRNAs.
This fascination with miRNAs continued, and Tewari decided to begin his own research program at the Fred Hutchinson Cancer Center in Seattle in 2005. In just three years, Tewari had established himself as a leader in the miRNA research field; his lab made the revolutionary discovery that extracellular miRNAs are found in circulation in a highly stable. This breakthrough led Tewari to pursue the potential of miRNAs to be used as biomarkers, revolutionizing cancer diagnosis and treatment.
In 2014, Tewari relocated his research to his alma mater, the University of Michigan in Ann Arbor. Michigan has provided a multitude of opportunities to intensify and expand the lab's research capabilities and positive impact.
Dr. Tewari has received multiple awards for innovation, including the Damon-Runyon Rachleff Innovation Award and the Presidential Early Career Award for Scientists and Engineers awarded by President Obama.
When Dr. Tewari began his MD/PhD at the University of Michigan in 1990, the world was largely unfamiliar with micro RNA (miRNA). When Dr. Tewari received his degree seven years later, a single miRNA had been discovered. The conversation about miRNA was just beginning as he headed to Harvard for his postdoctoral research.
Tewari first heard about these nucleotide sequences while working alongside a colleague researching protein networks. Captivated by the ability of miRNAs to prevent genes from being translated into proteins, Tewari dedicated much of his time to investigating their full capabilities, particularly those of circulating miRNAs.
This fascination with miRNAs continued, and Tewari decided to begin his own research program at the Fred Hutchinson Cancer Center in Seattle in 2005. In just three years, Tewari had established himself as a leader in the miRNA research field; his lab made the revolutionary discovery that extracellular miRNAs are found in circulation in a highly stable. This breakthrough led Tewari to pursue the potential of miRNAs to be used as biomarkers, revolutionizing cancer diagnosis and treatment.
In 2014, Tewari relocated his research to his alma mater, the University of Michigan in Ann Arbor. Michigan has provided a multitude of opportunities to intensify and expand the lab's research capabilities and positive impact.
Dr. Tewari has received multiple awards for innovation, including the Damon-Runyon Rachleff Innovation Award and the Presidential Early Career Award for Scientists and Engineers awarded by President Obama.
Contact Information |
Email: [email protected]
Phone: 734-764-5308 |
